Hodgkin Lymphoma — Lymphatic System Cancer

Hodgkin lymphoma is a specific haematological malignancy that originates within the lymphatic network. Unlike non-Hodgkin lymphomas, classical Hodgkin lymphoma is biologically defined by the presence of Reed-Sternberg cells—giant, multinucleated B-lymphocytes surrounded by an extensive inflammatory background. It is broadly categorised into classical Hodgkin lymphoma, which comprises roughly ninety-five percent of cases, and nodular lymphocyte-predominant Hodgkin lymphoma, a rarer and typically indolent subtype.

As the diseased lymphocytes accumulate, they cause lymph nodes to enlarge and can eventually spread across the lymphatic channels to adjacent or distant nodal chains. In advanced stages, malignant cells may infiltrate non-lymphatic organs, such as the spleen, liver, bone marrow, or lungs, compromising normal physiological function and requiring prompt systemic intervention.

Understanding a diagnosis of Hodgkin lymphoma allows patients and their families to navigate treatment pathways with clarity. Staging and subtype classification dictate whether therapy should involve limited-field radiotherapy, combination chemotherapy, or newer targeted approaches. Because Hodgkin lymphoma has a high rate of response to modern medical therapies, precise staging helps oncologists select effective regimens while minimising long-term toxicity. Clear knowledge of the condition empowers individuals to monitor their symptoms, discuss fertility preservation early, and comply with essential follow-up protocols.

Definitive diagnosis requires an excisional or core needle lymph node biopsy to demonstrate Reed-Sternberg cells using immunohistochemistry. Typical markers include CD30 and CD15 positivity, with CD20 usually negative or variable in classical cases. Staging involves fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) scans. Blood investigations, including full blood count, erythrocyte sedimentation rate, liver function, and renal panels, evaluate systemic involvement.

Hodgkin lymphoma is itself a distinct haematological cancer. It is not an epithelial tumour or solid carcinoma. However, its management requires differentiation from non-Hodgkin lymphomas, leukaemia, and metastatic solid tumours that spread to lymph nodes, such as head and neck carcinomas or breast cancer. Furthermore, because previous treatments can sometimes increase secondary malignancy risks, long-term survivorship involves vigilance for secondary solid tumours.

Therapy is guided by anatomical stage and prognostic risk factors. Early-stage favourable disease often responds to abbreviated chemotherapy combined with involved-site radiotherapy. Advanced-stage disease typically requires multi-agent chemotherapy regimens. Targeted therapeutics, such as brentuximab vedotin (an antibody-drug conjugate directed against CD30) and immune checkpoint inhibitors (PD-1 blockers), are integrated into front-line or relapsed settings to improve control.